Invasive breast cancer is the endpoint of complicated evolutionary process starting in TDLU of mammary gland. It is the network of multiple-step mechanism including cell proliferation, differentiation, atypical intracellular expression and signaling leading to the misbalance between mammary epithelial cells and breast tissue microenvironment. The disruption of epithelial-stromal equilibrium can lead to the epithelial carcinogenesis, progressive stromal invasion and metastatic spread in the final stages. Although we know some of the histopathologic features in these mechanisms, the molecular profile of these events is still not adequately responded, and remains the scope for future research.

The current knowledge is pointing on dual functioning activity of breast tissue microenvironment on breast carcinogenesis. Once it can stimulate it, other time has abilities to block malign transformation, as well as eliminate the cells with malign phenotype [1]. The first reports describing the active role of tissue microenvironment signaling activity on breast carcinogenesis and character of malign cell clones, e.g. the form of tumor grade are more than 30 years old [2]. The technologic advance in the molecular and tissue cell biology, mainly through gene-expression profiling approaches, allowed us over the last decade to detect and actively describe the role of myoepithelial cells, fibroblasts, adipocytes, immune system cells, growth and hormone factors, extra-cellular matrix, and epithelial-mesenchymal transition in the complicated process of progressive epithelial cell transformation into the pre-invasive and invasive forms of breast lesions [3,4]. These breast tissue micro-environmental “structures” are currently commonly described by mammary pathologists when reporting findings from breast lesion biopsies. Moreover, these findings show the cancer phenotype specific linkages in their morphologic variability or achievement of invasive status. Typical example of such biologic variability in microenvironment modified and controlled carcinogenesis is the dual form (barrier escape / failure) of DCIS transition to invasive breast carcinoma. The barrier escape is associated with the topic disruption of myoepithelial cells line and basement membrane tumor cells, allowing them to migrate and spread into surrounding stroma. However, in the case of barrier failure the disruption of myoepithelial cells line and basement membrane occur generally in their whole extent, followed by massive lymphocyte infiltration and accumulation of myofibroblasts [5]. Apart of this, data in the literature are proving the direct impact of microenvironment on proliferation, differentiation, apoptosis, and metastatic spread in the final stages. Although we know some of the histopathologic features in these mechanisms, the molecular profile of these events is still not adequately responded, and remains the scope for future research.

The progress in health directed technology is moreover associated with the advances in molecular profiling of breast carcinomas and subsequent growth of personalized medicine. It is well accepted, that the breast carcinoma is one of the most heterogeneous types of human cancer that integrates variable spectra of epithelial and stromal components with immense functional impact on affected subject. Based on some of them (e.g. ER, PgR, Her-2, MiB-1, Ki67, cytokeratines, etc...) we can recognize two most frequent (ductal / lobular) and more than 30 other histological subtypes of breast carcinomas [11]. This large phenotype variability is mainly the result of different carcinogenesis mechanisms and microenvironmental signaling. Supporting data from large follow-up studies indicate that even basic clinical-pathologic parameters of both most frequent types of breast cancer (ductal / lobular) can be similar, e.g. tumor size, grade or stage; the overall survival, disease-free survival rate, loco-regional recurrence rate or distant metastases free interval is markedly different [12,13]. This heterogeneity was confirmed by the epidemiologic, age, race and ethnic directed studies, and molecular or pathology focused studies bringing new insights into the features resembling hormonal expression, proliferative, apoptotic, migration, adhesion and/or metastatic activity, as well as histopathological evidence of e.g. (neo)adjuvant therapy. All these new findings gradually changed the routine concept of breast cancer patient selection into specific groups (e.g. low/high grade, ER positive/negative, Her-2 positive/negative, chemotherapy response sensitive/negative subject). Furthermore, not only progress in diagnostic approaches in pathology (H&E → IHC → CISH/FISH), but also progress in breast cancer molecular biology (cDNA, miRNA expression, clonal heterogeneity) and clinical follow-up studies (survival → recurrence → race, age phenotype, stage and therapeutic protocol used specificities in disease behavior) allowed the transition from many years used routine oncologic management, of invasive status. Typical example of such biologic variability in microenvironment modified and controlled carcinogenesis is the dual form (barrier escape / failure) of DCIS transition to invasive breast carcinoma. The barrier escape is associated with the topic disruption of myoepithelial cells line and basement membrane tumor cells, allowing them to migrate and spread into surrounding stroma. However, in the case of barrier failure the disruption of myoepithelial cells line and basement membrane occur generally in their whole extent, followed by massive lymphocyte infiltration and accumulation of myofibroblasts [5]. Apart of this, data in the literature are proving the direct impact of microenvironment on proliferation, differentiation, apoptosis, and metastatic spread in the final stages. Although we know some of the histopathologic features in these mechanisms, the molecular profile of these events is still not adequately responded, and remains the scope for future research.

The progress in health directed technology is moreover associated with the advances in molecular profiling of breast carcinomas and subsequent growth of personalized medicine. It is well accepted, that the breast carcinoma is one of the most heterogeneous types of human cancer that integrates variable spectra of epithelial and stromal components with immense functional impact on affected subject. Based on some of them (e.g. ER, PgR, Her-2, MiB-1, Ki67, cytokeratines, etc...) we can recognize two most frequent (ductal / lobular) and more than 30 other histological subtypes of breast carcinomas [11]. This large phenotype variability is mainly the result of different carcinogenesis mechanisms and microenvironmental signaling. Supporting data from large follow-up studies indicate that even basic clinical-pathologic parameters of both most frequent types of breast cancer (ductal / lobular) can be similar, e.g. tumor size, grade or stage; the overall survival, disease-free survival rate, loco-regional recurrence rate or distant metastases free interval is markedly different [12,13]. This heterogeneity was confirmed by the epidemiologic, age, race and ethnic directed studies, and molecular or pathology focused studies bringing new insights into the features resembling hormonal expression, proliferative, apoptotic, migration, adhesion and/or metastatic activity, as well as histopathological evidence of e.g. (neo)adjuvant therapy. All these new findings gradually changed the routine concept of breast cancer patient selection into specific groups (e.g. low/high grade, ER positive/negative, Her-2 positive/negative, chemotherapy response sensitive/negative subject). Furthermore, not only progress in diagnostic approaches in pathology (H&E → IHC → CISH/FISH), but also progress in breast cancer molecular biology (cDNA, miRNA expression, clonal heterogeneity) and clinical follow-up studies (survival → recurrence → race, age phenotype, stage and therapeutic protocol used specificities in disease behavior) allowed the transition from many years used routine oncologic management,
including surgery and adjuvant therapy to individually tailored chemo- and/or hormonal therapy. The oncologic practice proved that stratification of the patients with breast cancer only by common prognostic and predictive parameters into risk groups and subsequent treatment protocols is not effective for everybody, and has limitations in the prediction of future biologic behavior of the disease [14,15]. This experience has started a huge rise in genomic and molecular analyses of breast cancer and/or histologically normal tumor surrounding tissue focusing on the improvements in diagnostic and prognostic specificity, and prediction of adjuvant therapeutic sensitivity. Thus, we are being spectators of revolutionary transition from morphologic phenotype description to molecular taxonomy of breast carcinomas [16]. This taxonomy based on specific multigene-expression features of each breast cancer types reflects their biologic uniqueness. It is evident that this molecular approach can not only enrich, but has a potential to substitute traditional models of prognostic and predictive parameters (PPP) assessment in selection of patients for adjuvant management [17], that can be individually different for each patient [18-20].

The use of gene signatures in adjuvant management in women with breast cancer has brought new insights into the selection of therapeutic approaches and cost-benefit analyses. It is evident in oncology practice that response to any treatment is individually specific in the expression of side effects, relapses or remissions of the disease, though patients are stratified into the same risk group with similar disease features and stage, (Figure 1).

Therefore, adequate surgical interventions and the correct use of tests and tools, which can determine the optimal therapy for the patients, have to become the indispensable approach to be made by every physician when counseling their oncologic patients in the aim to achieve the best clinical outcome, and alleviate symptoms related to treatments strategies. This issue is focused on some of this aspects, e.g. age related comorbidity, oncological safety of surgery and specific determinants for improvement in individual therapy for hormonal receptor positive metastatic breast cancer [21-24]. I hope the readers will find this aspects of breast cancer management useful and will transfer and access new data for patient information.

All patients: IDC, G2, ER+, N1, Her-2 negat

Responders / No SE

Responders / With SE

Non-responders / With SE

Non-responders / No SE

Figure 1: Model of adjuvant chemotherapy effectiveness in therapeutic approaches with similar chemotherapy protocols used based only on common prognostic-predictive parameters without assessment of individual gene profile of carcinosmas. (All patients belong to the same risk group of disease, have similar histologic features, stage of the disease and adjuvant chemo-therapy protocol used. However, the true benefit – Responders without side effect accounts only for 25%. Fifty% of patients does not benefit from chemotherapy selected on the results from common PPP).

Altogether, I believe that there is a good trend and situation in the healthcare system to support our need for new insights into the process of breast carcinogenesis, role of tumor and surrounding tissue microenvironment signaling activity, phenotype determination and molecular profiling of breast carcinomas in the great aim to bring down all barriers between basic, translational research and the clinical application for the benefit in breast cancer patients worldwide.

Acknowledgement

I declare no conflict of interest. The work was supported by grant VEGA 1/0068/09 and project ITMS: 26220120036 Centre of excellence for perinatology research (CEPV II) co-financed from EU sources.

References


